Publications by authors named "Mihan Porabdollah"

3 Publications

  • Page 1 of 1

Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens.

Hum Antibodies 2021 Feb 26. Epub 2021 Feb 26.

Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Background: There are few studies to compare antibody response against anti-spike (S) and anti- nucleoprotein (N) SARS-CoV-2.

Objective: The aim of this study was to evaluate the IgG antibody production against S and N antigens of the virus and their correlation with the time and severity of the disease.

Methods: The IgG antibodies against S and N antigens of SARS-CoV-2 in serum specimens 72 symptomatic patients who tested real-time reverse transcription polymerase chain reaction positive for SARS-CoV-2 were detected using the ELISA technique. Different antibody response was compared and the correlation with the time from disease onset and the severity was evaluated.

Results: Forty-eight of 72 (67%) patients tested positive for anti-SARS-CoV-2 antibodies, while 24 (33%) did not have detectable antibodies. Comparison of antibody levels for N and S antibodies showed that they correlate with each other well (r= 0.81; P< 0.001). However, sensitivity of anti-S SARS-CoV-2 IgG and anti-N SARS-CoV-2 IgG was 30% and 60%, during the first 7 days after symptom onset (r= 0.53; P= 0.111), but increased to 73% and 68% at more than 1-week post symptom onset (r= 0.89, P= 0.111), respectively. Cases with positive IgG response showed a decreased CD8 cell percentage compared to the negative IgG groups (26 ± 14 vs. 58 ± 32, p= 0.066 in anti-N IgG group and 28 ± 15 vs. 60 ± 45, p= 0.004 in anti-S IgG group, respectively).

Conclusion: Nearly one-third of the confirmed COVID-19 patients had negative serology results. Lower percent positivity at early time points after symptom onset (less than 1 week) was seen using anti-S SARS-COV-2 IgG kit compare to the anti-N SARS-CoV-2 IgG; therefore, clinicians should interpret negative serology results of especially anti-S SARS-CoV-2 IgG with caution.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3233/HAB-210440DOI Listing
February 2021

Characterization of melanoma-associated antigen-a genes family differential expression in non-small-cell lung cancers.

Clin Lung Cancer 2012 May 3;13(3):214-9. Epub 2011 Dec 3.

Department of Anatomical Pathology, Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Background: The melanoma-associated antigen (MAGE) genes families are found in different cancers, including non-small-cell lung cancers. These genes are silent in normal tissues, except for the testis. The goal of this study was to investigate the differentially expressed profile of the different MAGE genes subclass in non-small-cell lung cancer (NSCLC) tumoral tissue.

Methods: Formalin-fixed paraffin embedded NSCLC resected tissues were collected from 31 patients hospitalized in our referral hospital, and 29 patients were diagnosed with either squamous cell carcinoma (SCC) or adenocarcinoma (ADC). We used a nested reverse transcriptase-polymerase chain reaction, which comprised independent amplification of MAGE-A1, MAGE-A2, MAGE-A3/6, MAGE-A4, and MAGE-A12, to detect expression frequency of the MAGE-A family in lung tissue biopsies at both tumoral and nontumoral parts of patients' tissues.

Results: From 29 patients with diagnosis of either SCC (n = 16) or ADCs (n = 13), 58 samples were prepared. From 58 blocks sampled for this experiment, 37 tumoral tissue samples and 22 nontumoral tissue samples expressed at least one of the MAGE-A genes. MAGE-A4 gene had the highest incidence among all MAGE-A genes in both tumoral and nontumoral gens. In SCC and ADCs, the data showed expression of at least one of the MAGE-A genes in 59.4% and 69.2% of tumoral and nontumoral tissues, respectively.

Conclusion: The detection of the MAGE-A genes expression could be a molecular tumor marker for early diagnosis and potential targets for active immunotherapy in NSCLC, particularly in ADCs and SCC. Besides, the frequency of different subtypes of MAGE genes may vary in different regions of world.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2011.09.007DOI Listing
May 2012